Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a.

Anwar MI, Iqbal M, Yousef MS, Rahman M.

Microb Cell Fact. 2013 Nov 16;12:111. doi: 10.1186/1475-2859-12-111.

2.

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.

Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J.

Gastroenterology. 2014 Mar;146(3):812-821.e4. doi: 10.1053/j.gastro.2013.11.009. Epub 2013 Nov 18.

PMID:
24262279
3.

Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.

Lindström I, Kjellin M, Palanisamy N, Bondeson K, Wesslén L, Lannergard A, Lennerstrand J.

Infect Dis (Lond). 2015 Aug;47(8):555-62. doi: 10.3109/23744235.2015.1028097. Epub 2015 Apr 8.

PMID:
25851241
4.

Studies on the role of NS3 and NS5A non-structural genes of hepatitis C virus genotype 3a local isolates in apoptosis.

Sabri S, Idrees M, Rafique S, Ali A, Iqbal M.

Int J Infect Dis. 2014 Aug;25:38-44. doi: 10.1016/j.ijid.2014.01.010. Epub 2014 May 17.

5.

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J.

Gastroenterology. 2011 Sep;141(3):1067-79. doi: 10.1053/j.gastro.2011.06.004. Epub 2011 Jun 12.

PMID:
21699793
6.

Immunoreactivity assessment of hepatitis C virus NS3 protease and NS5A proteins expressed in TOPO cloning system.

Alaee M, Rajabi P, Sharifi Z, Farajollahi MM.

J Microbiol Immunol Infect. 2014 Aug;47(4):282-91. doi: 10.1016/j.jmii.2012.08.016. Epub 2012 Oct 4.

7.

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1291-303. doi: 10.1128/AAC.02164-12. Epub 2012 Dec 28.

8.

Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.

Chusri P, Kumthip K, Pantip C, Thongsawat S, O'Brien A, Maneekarn N.

Virus Res. 2015 Jan 22;196:37-43. doi: 10.1016/j.virusres.2014.11.003. Epub 2014 Nov 11.

PMID:
25445343
9.

Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.

Provazzi PJ, Mukherjee S, Hanson AM, Nogueira ML, Carneiro BM, Frick DN, Rahal P.

PLoS One. 2015 Dec 10;10(12):e0144638. doi: 10.1371/journal.pone.0144638. eCollection 2015.

10.

Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma.

El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H.

Hepatology. 2013 Aug;58(2):555-63. doi: 10.1002/hep.26205. Epub 2013 Jun 14.

PMID:
23281009
11.

Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.

Dal Pero F, Tang KH, Gerotto M, Bortoletto G, Paulon E, Herrmann E, Zeuzem S, Alberti A, Naoumov NV.

J Infect Dis. 2007 Oct 1;196(7):998-1005. Epub 2007 Aug 21.

PMID:
17763320
12.

Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany.

Walker A, Siemann H, Groten S, Ross RS, Scherbaum N, Timm J.

J Clin Virol. 2015 Sep;70:43-45. doi: 10.1016/j.jcv.2015.07.008. Epub 2015 Jul 8.

PMID:
26305818
13.

Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.

Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N.

J Viral Hepat. 2011 Apr;18(4):e117-25. doi: 10.1111/j.1365-2893.2010.01379.x. Epub 2010 Oct 19.

PMID:
20955493
14.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.

J Clin Virol. 2012 Aug;54(4):352-4. doi: 10.1016/j.jcv.2012.04.024. Epub 2012 Jun 1.

PMID:
22658798
15.

Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains.

Kramer M, Halleran D, Rahman M, Iqbal M, Anwar MI, Sabet S, Ackad E, Yousef MS.

PLoS One. 2014 Aug 11;9(8):e104425. doi: 10.1371/journal.pone.0104425. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e111263. Yousef, Mohammad [corrected to Yousef, Mohammad S]. PLoS One. 2014;9(12):e116131. Anwar, Muhmad Ikram [corrected to Anwar, Muhammad Ikram].

16.

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.

Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C.

PLoS One. 2015 Aug 28;10(8):e0134395. doi: 10.1371/journal.pone.0134395. eCollection 2015.

17.

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.

Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K.

Gut. 2013 Jul;62(7):1055-61. doi: 10.1136/gutjnl-2012-302600. Epub 2013 Jan 15.

PMID:
23322441
18.

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.

Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J.

Arch Virol. 2013 Sep;158(9):1907-15. doi: 10.1007/s00705-013-1687-6. Epub 2013 Apr 4.

PMID:
23553458
19.

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.

Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.

J Med Virol. 2014 Nov;86(11):1868-76. doi: 10.1002/jmv.24016. Epub 2014 Jul 23.

PMID:
25052594
20.

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.

Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D.

J Virol. 1998 Apr;72(4):2795-805.

Supplemental Content

Support Center